References
- Lechi A, Aorio E, Pancera P, Anesi P, Zannini G, Todeschini G, Cetto G. Pseudomonas septicaemia, a review of 60 cases observed in a university hospital. J Hosp Infect 1984; 5: 29–37
- Prentice H G, Sage R, Hann I, Hoffbrand V, Blacklock H, Noone P. The results of a randomized trial of empirical antibiotic treatment in febrile neutropenic patients with four beta-lactam/aminoglycoside combinations. Abstract, Third International Symposium on Infections in the Immunocom-promised Host. Toronto 1984
- Williams J D, Casewell M W. Ceftazidime: Proceedings of a Symposium held in London, 28–29 April 1981. J Antimicrob Chemother 1981; 8, Suppl. B
- Stokes E J. Clinical bacteriology3rd ed. Arnold, London 1968; 179
- Sanders C C, Sanders W E, Jr. Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamase and implication for the future. Rev Infect Dis 1983; 5: 639–648
- King A, Shannon K, Eykyn S, Phillips I. Reduced sensitivity to beta-lactam antibiotics arising during ceftazidime treatment of Pseudomonas aeruginosa infections. J Antimicrob Chemother 1983; 12: 363–70
- Rampling A, Warren R E, Bevan P C, Hogarth C E, Swirsky D, Hayhoe F GJ. Clostridium difficile in haematological malignancy. J Clin Pathol 1985; 38: 445–51
- Wittmann D H, Schassan H H, Kohler F, Seibert W. Pharmacokinetic studies of ceftazidime in serum, bone, bile, tissue fluid and peritoneal fluid. J Antimicrob Chemother 1981; 8: 293–297, Suppl. B